Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Inner Thoughts of Leonard Bernstein, the "Maestro".

2.

Patellar Resurfacing in Total Knee Replacement; Patient Messaging Trends

3.

Pancreatic Cancer: A Novel CD40 Agonist-Chemo Combo Shows Promise.

4.

Underprescribed for Alcohol Use Disorder is pharmacotherapy.

5.

Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot